https://www.anavex.com/post/anavex-...formation-on-anavex-2-73-avatar-phase-3-trial
Anavex Life Sciences Corp. (“Anavex” or the “Company”(Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today provides supplemental information on the ANAVEX®2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome.
Following the successful completion of U.S. Phase 2 Rett syndrome study (ANAVEX®2-73-RS-001) as announced in December 2020, and the knowledge gained from it, the AVATAR study (ANAVEX®2-73-RS-002) appropriately updated endpoints according to ICH guidelines were approved by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and in Australia by the Human Research Ethics Committees (HREC), where the AVATAR study was conducted. Subsequently the AVATAR study was updated from a Phase 2 to a Phase 3 study. The January 2022 update to the trial description in ‘clinicaltrials.gov’ was not a real-time communication and may have given the wrong impression of a late change of trial endpoints / phase of the study, which is not the case.
Based on the results of the AVATAR Phase 3 study (ANAVEX®2-73-RS-002) and the prior successful U.S. Phase 2 (ANAVEX®2-73-RS-001) study in adult patients with Rett syndrome, Anavex is planning to meet with the FDA to discuss the approval pathway. There are no FDA-approved drugs for Rett syndrome. ANAVEX®2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome.
- Forums
- ASX - By Stock
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
https://www.anavex.com/post/anavex-life-sciences-provides-supplem...
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B |
Open | High | Low | Value | Volume |
$20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1378 | $21.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.29 | 218 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 21.240 |
1 | 47 | 21.150 |
1 | 500 | 20.860 |
1 | 240 | 20.800 |
1 | 50 | 20.630 |
Price($) | Vol. | No. |
---|---|---|
21.300 | 12763 | 1 |
21.350 | 30 | 1 |
21.380 | 471 | 1 |
21.410 | 25 | 1 |
21.500 | 60 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online